Anvil Biosciences develops therapeutics, biologics and small molecules, with secondary interests in diagnostics, medical devices, and platform technologies. The firm's core competencies include Immunology Oncology, Infectious Disease, and Metabolism. The company offers licensing and consulting services. The company utilizes nucleic acid gene expression platforms to generate therapeutics in the autoimmune and cancer space and has therapeutics engine including next-gen plasmid DNA, synthetic mRNA, and oligonucleotide platform technologies.
